From bloodjournal.hematologylibrary.org at UNIVERSITY OF NEWCASTLE on January 30, 2014. For personal use only.

2014 123: 625-631 Prepublished online December 3, 2013; doi:10.1182/blood-2013-09-512749

Oxidative stress in angiogenesis and vascular disease Young-Woong Kim and Tatiana V. Byzova

Updated information and services can be found at: http://bloodjournal.hematologylibrary.org/content/123/5/625.full.html Articles on similar topics can be found in the following Blood collections Review Articles (493 articles) Vascular Biology (437 articles) Information about reproducing this article in parts or in its entirety may be found online at: http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests Information about ordering reprints may be found online at: http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprints Information about subscriptions and ASH membership may be found online at: http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtml

Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036. Copyright 2011 by The American Society of Hematology; all rights reserved.

From bloodjournal.hematologylibrary.org at UNIVERSITY OF NEWCASTLE on January 30, 2014. For personal use only.

Review Article

Oxidative stress in angiogenesis and vascular disease Young-Woong Kim and Tatiana V. Byzova Department of Molecular Cardiology, Joseph J. Jacobs Center for Thrombosis and Vascular Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH

Despite the damaging effect on tissues at a high concentration, it has been gradually established that oxidative stress plays a positive role during angiogenesis. In adults, physiological or pathological angiogenesis is initiated by tissue demands for oxygen and nutrients, resulting in a hypoxia/reoxygenation cycle, which, in turn promotes the formation of reactive oxygen species (ROS). The ROS can be generated either endogenously, through mitochondrial electron transport chain reactions

and nicotinamide adenine dinucleotide phosphate oxidase, or exogenously, resulting from exposure to environmental agents, such as ultraviolet or ionizing radiation. In many conditions, ROS promotes angiogenesis, either directly or via the generation of active oxidation products, including peroxidized lipids. The latter lipid metabolites are generated in excess during atherosclerosis, thereby linking atherogenic processes and pathological angiogenesis. Although the main mechanism of

oxidative stress-induced angiogenesis involves hypoxia-inducible factor/vascular endothelial growth factor (VEGF) signaling, recent studies have identified several pathways that are VEGF-independent. This review aims to provide a summary of the past and present views on the role of oxidative stress as a mediator and modulator of angiogenesis, and to highlight newly identified mechanisms. (Blood. 2014;123(5):625-631)

Introduction Angiogenesis is defined as the process of sprouting new blood vessels from preexisting vasculature. New blood vessel formation is essentially required for many physiological processes, such as embryogenesis, tissue repair, and organ regeneration.1 This process, however, needs to be finely balanced, because excessive or insufficient angiogenesis contributes to a number of pathologies, ranging from cancer, macular degeneration, and retinopathy of prematurity to impaired repair of ischemic tissues.2 Angiogenesis is a truly systemic process that requires the responses of multiple cell types, including endothelial, mural, inflammatory, and bloodderived cells.3 These cells participate in a range of processes, such as cell adhesion, migration, proliferation, and differentiation, thereby adding another level of complexity.4 Angiogenesis, either physiological or pathological, requires initiation by proangiogenic factors, exemplified by vascular endothelial growth factor (VEGF), placental growth factor, platelet-derived growth factor-B, transforming growth factor b, and angiopoietin-1 (ANG-1).2 In most situations, if not all, angiogenesis is closely interwoven with the mobilization of inflammatory cells.5 During physiological or repair processes, such as wound healing, the inflammation process is transient; most pathological conditions, exemplified by cancer, involve a continuous recruitment of inflammatory cells, which, in turn, serve as a substantial source of ROS.6 This functional connection between the inflammation-dependent generation of ROS and angiogenesis plays an important role during various stages of tumor progression, from its initiation stage to vascularization and metastasis. Moreover, in most pathologies, oxidative stress operates as part of a positive feedback mechanism, which gives it even more signification in the process.7 Oxidative stress, which is defined as an imbalance between prooxidant and antioxidant systems,7 can be both a cause and consequence of many vascular complications and serve as one of the biomarkers for these conditions. At the same time, well-

Submitted September 16, 2013; accepted November 24, 2013. Prepublished online as Blood First Edition paper, December 3, 2013; DOI 10.1182/blood2013-09-512749.

BLOOD, 30 JANUARY 2014 x VOLUME 123, NUMBER 5

controlled oxidative stress may be beneficial for angiogenesis during tissue repair. In this review, we summarize the history and recent findings on the relationship between oxidative stress and angiogenesis, and discuss the implications of oxidative stress on pathological conditions and therapeutic strategies.

ROS generation and accumulation Chemistry of oxidative stress

By 1 electron at a time, oxygen can be sequentially reduced to 4 components: superoxide anion, hydrogen peroxide, hydroxyl radical, and a water molecule.8 During this reduction-oxidation (redox) reaction, ROS are produced as intermediates in vivo. Superoxide anion is known to be a main contributor to the generation of most ROS and a crucial mediator of electron transport chain reactions in mitochondria. Usually, superoxide anion is rapidly removed through dismutation to hydrogen peroxide, either spontaneously or by superoxide dismutases (SOD).8,9 Neutrophil-secreted myeloperoxidase further converts hydrogen peroxide and chloride into highly reactive hypochlorite. For vascular cells, superoxide anion and hydrogen peroxide appear to be particularly important because they are able to activate diverse pathways to induce either new vascular growth, or vascular dysfunction and destruction.10 ROS can be generated by all vascular cell types, including endothelial cells, smooth muscle cells, adventitial fibroblasts, and perivascular adipocytes.11 There are 2 main endogenous sources in the vasculature: mitochondrial electron transport chain reactions and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase.11-13 In mitochondria, more than 95% of oxygen consumed by cells is used to yield water molecules through redox reactions.14 © 2014 by The American Society of Hematology

625

From bloodjournal.hematologylibrary.org at UNIVERSITY OF NEWCASTLE on January 30, 2014. For personal use only. 626

KIM and BYZOVA

Particularly, at complex I and III in the transport chain, premature electron leakage to oxygen occurs, which causes less than 4% of oxygen to be reduced to superoxide anion, but not to water, generating oxidative stress.8,10 NADPH oxidase, an enzyme that generates superoxide anion by transferring electrons from NADPH to oxygen, is recognized as a major source of ROS in many cell types, including endothelial and smooth muscle cells.10,13-17 It is important to note that in many conditions, the respiratory (oxidative) burst of inflammatory cells, such as neutrophils and monocytes, is the main contributing factor to ROS levels in a number of vascular pathologies. For example, myeloperoxidase is believed to be one of the main players in vasculitis and coronary artery disease.18 One of the main consequences of ROS presence is peroxidation of proteins and lipids, resulting in their functional modifications.19,20 In vivo, lipid peroxidation affects cellular membrane lipids, including the polyunsaturated fatty acid (PUFA) part of phospholipids, which are particularly prone to oxidation, generating a new array of biologically active agents.19 These oxidationgenerated secondary compounds may be even more destructive than ROS themselves.20 In sum, oxidative stress entails not only the production and accumulation of ROS, but also oxidative stressinduced metabolic products generated through lipid and protein peroxidation.

Oxidative stress as mediator of angiogenesis

ROS act as a double-edged sword in the vasculature because chronically produced or highly concentrated ROS are detrimental for most tissues, whereas transient or low levels of ROS are able to activate signaling pathways that eventually promote regeneration and growth.21,22 Thus, ROS are implicated, either directly or indirectly, in the process of physiological, pathological, and excessive angiogenesis. One of the early implications of ROS in angiogenesis resulted from the studies using thiol-containing compounds, which were shown to inhibit macrophage-derived proangiogenic activity, as the conditioned medium from gold sodium thiomalate-treated macrophages potently reduced angiogenesis in rat corneas.23,24 Although an effect was somewhat indirect, the follow-up studies from the same group demonstrated that thiol-containing compounds acting as ROS scavengers may inhibit production of angiogenic factors by macrophages.23-25 A number of studies using hydrogen peroxide have concluded that at a high concentration, hydrogen peroxide causes endothelial injury; however, at a low concentration, it generally stimulates angiogenesis, as hydrogen peroxide .125 mM induces lethal vascular endothelial cell injury, but between 0.1 and 10 mM, the tube formation was obtained in the endothelial cells from the bovine thoracic aorta.26-28 It has been suggested that tumor angiogenesis is triggered by hydrogen peroxides, which are produced in large amounts by tumor cells themselves.28,29 Several studies have shown that conditions of hypoxia followed by reoxygenation, but not hypoxia alone, accelerate tubular morphogenesis in human microvascular endothelial cells and promote myocardial angiogenesis in animal models of chronic myocardial infarction.30,31 In human umbilical vein endothelial cells (HUVECs), leptin increases the accumulation of ROS, thereby promoting angiogenesis.32 These conclusions are further supported by studies using oxidase inhibitors and general antioxidants. NADPH oxidase

BLOOD, 30 JANUARY 2014 x VOLUME 123, NUMBER 5

Figure 1. Schematic representation of ROS generation and its effect on angiogenesis. Two main mechanisms are shown: ROS effect on known components of HIF-VEGF/VEGFR2 signaling pathway and VEGF-independent mechanism involving generation of lipid oxidation products. MPO, myeloperoxidase.

inhibitors, such as diphenyliodonium and apocynin, as well as free radical scavengers, such as mannitol and catalase, appear to inhibit angiogenesis.25,33 A similar effect has been observed in studies using a potent ROS scavenger, N-acetylcysteine.34 Adenoviral overexpression of extracellular SOD inhibited tumor vascularization and growth melanoma.35 Thus, the antiangiogenic effects of antioxidants have further confirmed the overall proangiogenic function of ROS. This notion is further supported by mouse genetic studies. The vascular remodeling induced by ANG-1 is more prominent in catalase knockout mice than in wild-type controls.36 Nox1 knockout mice, lacking a component of NADPH oxidase, have shown a reduced endothelial cell migration and reduced formation of tube-like structures.37 Likewise, a lack of NADPH oxidase 2 (Nox2) substantially impairs VEGF-induced angiogenesis and neovascularization in the ischemic hindlimb model.38,39 ANG1-stimulated ROS, endothelial cell migration, and sprouting from aortic rings are suppressed in the mice that are deficient in p47phox, another component of NADPH oxidase.40

Mechanisms of oxidative stress-induced angiogenesis Oxidative stress, oxidized products, and VEGF signaling

VEGF is the most potent and primary endothelial specific angiogenic growth factor, both in physiological and pathological conditions. VEGF signaling is ultimately required for normal vascular development and homeostasis, but it is also actively engaged in tumor progression by promoting growth of tumor vasculature.41 This signaling pathway often seems to be affected by ROS. Exogenous ROS stimulate the induction of VEGF expression in various cell types, such as endothelial cells, smooth muscle cells, and macrophages, whereas VEGF induces endothelial cell migration and proliferation through an increase of intracellular ROS.38,42-45 Thus, the reciprocity between oxidative stress and angiogenesis has been centered on the VEGF signaling pathway (Figure 1).10 A number of studies have demonstrated this positive interrelationship between ROS and angiogenesis. Hydrogen peroxide induces VEGF expression in vascular smooth muscle cells, as well as endothelial cells, and thereby promotes angiogenic responses.42,44 In several pathologies, exemplified by diabetic retinopathy and injured arteries, ROS-mediated angiogenesis is

From bloodjournal.hematologylibrary.org at UNIVERSITY OF NEWCASTLE on January 30, 2014. For personal use only. BLOOD, 30 JANUARY 2014 x VOLUME 123, NUMBER 5

strongly associated with VEGF expression.42,46,47 At the same time, VEGF further stimulates ROS production through the activation of NADPH oxidase in endothelial cells.12 VEGF-induced superoxide anion production is regulated by components of NADPH oxidase, including Rac1, Nox1, and Nox2, as it is significantly inhibited in HUVECs by either overexpression of dominant negative Rac1 or transfection of Nox2 antisense oligonucleotides.38 In addition, overexpression of Nox1 increases VEGF expression in NIH3T3 fibroblast and DU-145 prostate cancer cells, and VEGF receptor (VEGFR) 2 expression in endothelial cells of tumor blood vessels, through ROS production.48 ROS also affect VEGFstimulated VEGFR2 dimerization and autophosphorylation, which are required for VEGFR2 activation and subsequent angiogenesis (Figure 1).38,49 Likewise, products of oxidation exemplified by oxidized phospholipids (OxPLs) are reported to interact with VEGFR2, and thereby stimulate angiogenesis via Src-mediated signaling.50 Thus, ROS promote angiogenic responses in various tissues by operating both upstream and downstream of VEGF/ VEGFR2 signaling. There are a number of compelling studies reporting the augmentation of angiogenesis by oxidation products (eg, oxidized lipids, which often operate via the hypoxia-inducible factor (HIF)/ VEGF pathway). OxPLs have been found to stimulate endothelial cell sprouting in vitro and promote capillary growth in vivo.51 OxPLs also stimulate VEGF expression in vivo, as well as in several cell lines in vitro, as oxidized 1-palmitoyl-2-arachidonoylsn-glycero-3-phosphocholine increases VEGF messenger RNA expression in HUVECs, human adult skin fibroblasts, primary human bronchial epithelial cells, human and primary mouse keratinocytes, and epithelial tumor cell lines of different tissue origin, such as MCF-7, Hep3B, and HeLa.51 Particularly, oxidized low density lipoproteins (oxLDL), which are generated by oxidative stress also increase VEGF expression and its messenger RNA stability in human macrophages.52 OxLDL also strongly induces HIF-1a, as well as VEGF expression in monocyte-macrophages and significantly increases tube formation in cocultured endothelial cells.53,54 HIF-1a inhibition abrogates the proangiogenic effect of oxLDL in vivo, suggesting that the HIF-1a pathway is a possible molecular mechanism by which oxLDL induces angiogenesis.53 VEGF-independent mechanisms of oxidation-induced angiogenesis

Several recent studies have identified new mechanisms of ROSactivated angiogenesis that operate in a VEGF-independent manner. One of these mechanisms mediating proangiogenic function of ROS involves the generation of new lipid oxidation products with proangiogenic activities.55,56 One of the PUFA of phospholipids, docosahexaenoic acid (DHA), is recognized as a highly abundant and oxidation prone substrate in many human tissues, especially in the retina and brain.19,57 PUFA-derived g-hydroxyalkenal oxidized phospholipids are known to produce v-carboxyalkylpyrrole (CAP) modifications of proteins after the lipolysis of intermediate phospholipid adducts.58 As such, v-carboxyethylpyrrole (CEP) protein adducts are generated from the oxidation of 1-palmityl-2-docosahexanoyl-sn-glycerophosphocholine.58 As the end product of DHA oxidation, CEP serves as an important biomarker for oxidative stress-induced vascular pathologies in retina, such as age-related macular degeneration.CEP is generated in retinas with age-related macular degeneration, during wound healing, and also in highly vascularized tumors, where it

OXIDATIVE STRESS IN ANGIOGENESIS

627

promotes angiogenesis.58-60 The neutralization of endogenous CEP in mice by a CEP-specific antibody impairs wound healing, tissue revascularization, and diminishes tumor angiogenesis, thereby demonstrating the key role of this pathway in various models of angiogenesis.59 Importantly, the molecular mechanism by which CEP induces angiogenesis is found to be independent on VEGF/ VEGFR2 and operates via activation of the Toll-like receptor (TLR) 2/MyD88 pathway.59 This leads to the activation of Rac1 to promote cell migration and angiogenesis.59 Curiously, Rac1 is a component of NADPH oxidase, suggesting that in certain conditions, this pathway may be interconnected with VEGF-mediated or NADPH oxidase-mediated signaling in the angiogenic network (Figure 1).61 Likewise, other studies have convincingly shown that TLRs play important roles beyond innate immunity and function as significant contributors to angiogenesis.62 To date, several proangiogenic ligands of TLRs, such as lipopolysaccharide as a TLR4 ligand, poly(I:C) as a TLR3 ligand, macrophage-activating lipopeptide-2 as a TLR2/6 ligand, and CEP as a TLR2 ligand, were generated by oxidative stress.63-68 Another recent study reports that peroxidized unsaturated fatty acids stimulate TLR4 signaling on endothelial cells, leading to nuclear factor kB activation, as TLR4 was acutely translocated to caveolae/raft membranes upon treatment.69 Considering the angiogenic activity of lipopolysaccharide/TLR4 signaling, this peroxidized unsaturated fatty acids-mediated TLR4 activation may have an effect on angiogenesis in vivo. TLR signaling has also been shown to affect the HIF/VEGF pathway of angiogenesis. TLR2 has been shown to modulate the expression of HIF-1a, which activates the VEGF promoter in response to hypoxia (Figure 1).70 Another comprehensive study has connected oxidative stress and VEGF-independent angiogenesis, and has identified a new function of ataxia-telangiectasia mutated (ATM) kinase in oxidative defense.71 ATM is selectively activated in immature blood vessels in response to ROS accumulation.71 Unlike CEP-TLR2 mediated angiogenesis, ATM-induced angiogenesis is only limited to promoting pathological responses, such as excessive tumor angiogenesis.71 ATM promotes the proliferation of endothelial cells by suppressing high levels of ROS. The downstream of the ROS-induced ATM activation pathway is identified as p38a, as the increased ROS by ATM deficiency activate p38 both in vitro and in vivo.71 Importantly, ATM deficiency synergistically enhances the antiangiogenic effect of VEGF inhibition in mouse tumor growth and angiogenesis by SU1498, a specific VEGFR2 inhibitor, indicating a VEGFindependent proangiogenic role of ATM.71

Oxidative stress induced-angiogenesis in pathologies Angiogenic processes influenced by oxidative stress

Angiogenesis represents several interwoven components, including endothelial responses and the mobilization of proangiogenic bone marrow (BM)-derived cells; oxidative signaling has been found to modulate all of these processes.72 The release of proangiogenic cells from the BM has been shown to be dependent on ROS signaling, as Nox2 knockout mice exhibited impaired ischemia-induced blood flow recovery, which is linked to ROS levels in BM mononuclear cells and their mobilization from the BM.73 Intracellular ROS production mediated by NADPH

From bloodjournal.hematologylibrary.org at UNIVERSITY OF NEWCASTLE on January 30, 2014. For personal use only. 628

KIM and BYZOVA

components Nox2 and Nox4 promotes proliferation and survival of endothelial cells via p38, extracellular signal regulated kinase, and Akt signaling.74-78 A scaffolding protein IQGAP1 appears to be involved in the different stages of angiogenic processes, including ROS-mediated disruption of VE-cadherin–containing adherence junctions and VEGF2 signaling, both of which are known to promote endothelial migration.79,80

BLOOD, 30 JANUARY 2014 x VOLUME 123, NUMBER 5

diminished in ATM-deficient mice in which excessive ROS are inhibited.71 Pathological angiogenesis promotes atherogenic processes by increasing both macrophage infiltration and the thickening of blood vessel wall.12 Similar to other pathologies, this angiogenesis is highly and directly augmented by ROS and ROS products; this is represented by metabolites of lipid oxidation, which are generated and accumulated in plasma and the vessel wall of both mice and humans.51,99-101

Physiological angiogenesis by oxidative stress

Physiological angiogenesis in adult organisms is required for tissue repair and remodeling processes, such as wound healing, skeletal remodeling, and female reproduction.2 In wound healing, angiogenesis is induced by tissue hypoxia and ROS, which either stimulate macrophages, fibroblasts, endothelial cells, and keratinocytes to produce VEGF,6,43,81-83 or operate in a VEGFindependent fashion.59 During endochondral ossification during longitudinal bone growth, increasing ROS promote chondrocyte hypertrophy, which, in turn, induces angiogenesis. Antioxidant treatment (eg, by N-acetylcysteine) inhibits these processes.84 Angiogenesis is important for cyclical regeneration of endometrium in the menstrual cycle and is also regulated by ROS.85 SOD expression shows a cyclical variation in the endometrium, and its activity decreases in the late secretory phase, whereas lipid peroxide levels increase.86 Another study has reported that the vascular density is significantly increased in the late secretory phase as compared with the late proliferative phase, supporting the timely requirement of ROS on the angiogenic potential of endometrium.87

Pathological angiogenesis by oxidative stress

Pathological angiogenesis is fundamentally similar to physiological angiogenesis and aims to promote new blood vessels to supply oxygen and nutrients. However, pathological angiogenesis proceeds in an uncontrolled and unbalanced manner, resulting in an excessive and abnormal vascular pattern.2 In most pathologies ranging from tumorigenesis, eye diseases, and atherosclerosis, angiogenesis is greatly affected by oxidative stress.2,16,88 In tumors, both tumor and stromal cells, including inflammatory cells, produce substantial amounts of ROS.29,89,90 Nox1-induced ROS production activates oncogenic Ras signaling and promotes upregulation of VEGF, which, in turn, augments tumor angiogenesis.91 In prostate cancer, NADPH oxidase-derived ROS causes HIF-1a activation and the subsequent release of VEGF.92 Often, inhibition of both VEGF and oxidative pathways produces a synergistic effect on angiogenesis.59 In retinopathies, where abnormal angiogenesis is regarded as a hallmark and a cause of pathology,2 ROS production is highly elevated due to high oxygen tension and insufficient ROS scavenging by antioxidants, such as vitamins C and E and copper/zinc SOD.93-95 As a result, superoxide anion and hydrogen peroxide levels have shown to be substantially elevated in animal models of diabetic retinopathy or retinopathy of prematurity.96 Even normal retinas seem to be particularly sensitive to oxidative stress, due to a high consumption of oxygen, high levels of oxidation substrates (eg, PUFAs), and exposure to light.97 DHA, one of the easily oxidizable PUFAs, represents 60% of the PUFAs in the retina57 and the product of its oxidation serves as a biomarker for oxidative stress-induced injury in age-related macular degeneration.60,98 Likewise, ischemic retinopathy is substantially

Therapeutic implications

As a master regulator for angiogenesis, VEGF and its pathway have served as primary targets for antiangiogenic therapy.102-103 The current view on the anti-VEGF therapy, using an anti-VEGF antibody or VEGFR inhibitors, is not as optimistic as it was several years ago.104 Despite rather disappointing results of recent clinical studies, drug targeting of the angiogenic process stimulated and accelerated the development of alternative antiangiogenic approaches.103-104 Moreover, pathological angiogenesis shares many pathways, most notably VEGF/VEGFR2, with physiological processes, thus hindering both the success and safety of anti-VEGF therapy.105 Despite the great importance of VEGF during oxidative stress-induced angiogenesis, there are a variety of VEGFindependent signaling pathways implicated in pathological angiogenesis, such as the ROS/ATM/p38a and CEP/TLR2/MyD88 pathway, which may reduce the efficacy of anti-VEGF therapy.55 At the same time, inhibition of VEGF pathway may disturb the homeostatic maintenance of normal vasculature and result in delayed wound healing, hypertension, proteinuria, thrombosis, and hemorrhage.105-107 Thus, there is a need for a specific target discriminating pathological vasculature from a healthy one. In this regard, it is noteworthy that ATM is selectively activated in immature pathological blood vessels, but not in normal vessels, in response to ROS, suggesting the potential of anti-ATM therapy.71 In most pathologies, it may be beneficial to target oxidative stress, per se. One possibility is the use of pharmacological inhibitors of NADPH oxidase, which is the main source of ROS in vasculature.108-109 However, the studies using such inhibitors in vivo animal models15,16 are limited. Another strategy to diminish oxidative stress-induced pathological angiogenesis is the use dietary antioxidants, which also may prevent vascular pathologies.110 For instance, vitamins C and E reduce VEGF and VEGFR2 expression in Apolipoprotein E knockout mice.111 Both red wine polyphenolic compounds and green tea polyphenols inhibit angiogenesis by reducing the expression of VEGF and matrix metalloproteinase-2.112 Similarly, resveratrol, a natural compound found in grapes and red wine, suppresses angiogenesis, significantly inhibits fibrosarcoma growth, and delays angiogenesis-dependent wound healing in mice.113 However, most of these antioxidants are nonspecific and affect both pathological and physiological angiogenesis. Furthermore, it is difficult to determine the optimal dose of the inhibitor for each pathological condition in each individual, resulting in additional limitations of anti-VEGF therapy, NADPH oxidase inhibitors, or general antioxidants. Therefore, there is a need for a better understanding of the precise molecular mechanisms behind oxidative stress-induced angiogenesis and the identification of markers and processes specific for either pathological or physiological angiogenesis.

From bloodjournal.hematologylibrary.org at UNIVERSITY OF NEWCASTLE on January 30, 2014. For personal use only. BLOOD, 30 JANUARY 2014 x VOLUME 123, NUMBER 5

OXIDATIVE STRESS IN ANGIOGENESIS

629

Conclusions

Acknowledgments

As in the drawings of Maurits Escher, multiple components of angiogenesis are interlinked with oxidative stress. The former process cannot be regarded simply as either friend or foe because it appears to have different and often opposite functions, similar to snake venoms, which can either deliver an antidote or result in severe damage in excessive quantities. Physiologically appropriate levels of ROS, generated either in restricted amounts or in a transient fashion, are essentially required to promote physiological angiogenesis and homeostatic maintenance of healthy vasculature. However, uncontrolled continuous ROS production will ultimately contribute to pathology and cause tissue damage. It is clear that oxidative stress-dependent angiogenesis is an important contributor to the progression of cancers and chronic diseases. Multifaceted pathways involved in oxidative stress-induced angiogenesis have yet to be investigated. Possible antioxidative strategies must be highly selective and may affect the production or scavenging of ROS or their metabolic products.

The authors thank Emelye Crehore for her assistance with manuscript proofreading. This work was supported by a research grant from the National Institutes of Health, National Heart, Lung, and Blood Instutute (HL071625) (T.V.B.) and an American Heart Association Postdoctoral Fellowship (POST14570001) (Y.-W.K.).

Authorship Contribution: Y.-W.K and T.V.B wrote the paper, and reviewed and approved the final version of the manuscript. Conflict-of-interest disclosure: The authors declare no competing financial interests. Correspondence: Tatiana Byzova, Cleveland Clinic, 9500 Euclid Ave, NB-50, Cleveland, OH 44195; e-mail: [email protected].

References 1. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004;56(4):549-580.

14. Brand MD, Affourtit C, Esteves TC, et al. Mitochondrial superoxide: production, biological effects, and activation of uncoupling proteins. Free Radic Biol Med. 2004;37(6):755-767.

26. Shimizu S, Nomoto M, Yamamoto T, Momose K. Reduction by NG-nitro-L-arginine of H2O2induced endothelial cell injury. Br J Pharmacol. 1994;113(2):564-568.

2. Chung AS, Ferrara N. Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol. 2011;27:563-584.

15. Ushio-Fukai M, Nakamura Y. Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett. 2008; 266(1):37-52.

27. Burdon RH, Gill V, Rice-Evans C. Oxidative stress and tumour cell proliferation. Free Radic Res Commun. 1990;11(1-3):65-76.

3. Noonan DM, De Lerma Barbaro A, Vannini N, Mortara L, Albini A. Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer Metastasis Rev. 2008;27(1): 31-40. 4. Jain RK. Molecular regulation of vessel maturation. Nat Med. 2003;9(6):685-693. 5. Costa C, Incio J, Soares R. Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis. 2007;10(3):149-166. 6. Schreml S, Szeimies RM, Prantl L, Karrer S, Landthaler M, Babilas P. Oxygen in acute and chronic wound healing. Br J Dermatol. 2010; 163(2):257-268. 7. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med. 2010; 49(11):1603-1616. 8. Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol. 2003;552(Pt 2): 335-344. 9. Fukai T, Ushio-Fukai M. Superoxide dismutases: role in redox signaling, vascular function, and diseases. Antioxid Redox Signal. 2011;15(6): 1583-1606. 10. Bir SC, Kolluru GK, Fang K, Kevil CG. Redox balance dynamically regulates vascular growth and remodeling. Semin Cell Dev Biol. 2012; 23(7):745-757. 11. Touyz RM, Briones AM. Reactive oxygen species and vascular biology: implications in human hypertension. Hypertens Res. 2011; 34(1):5-14. 12. Ushio-Fukai M, Alexander RW. Reactive oxygen species as mediators of angiogenesis signaling: role of NAD(P)H oxidase. Mol Cell Biochem. 2004;264(1-2):85-97. 13. Takac I, Schroder ¨ K, Brandes RP. The Nox family of NADPH oxidases: friend or foe of the vascular system? Curr Hypertens Rep. 2012; 14(1):70-78.

16. Coso S, Harrison I, Harrison CB, et al. NADPH oxidases as regulators of tumor angiogenesis: current and emerging concepts. Antioxid Redox Signal. 2012;16(11):1229-1247. 17. Lassegue ` B, San Mart´ın A, Griendling KK. Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system. Circ Res. 2012;110(10):1364-1390. 18. Lau D, Baldus S. Myeloperoxidase and its contributory role in inflammatory vascular disease. Pharmacol Ther. 2006;111(1):16-26. 19. Gueraud ´ F, Atalay M, Bresgen N, et al. Chemistry and biochemistry of lipid peroxidation products. Free Radic Res. 2010;44(10): 1098-1124. 20. Negre-Salvayre A, Auge N, Ayala V, et al. Pathological aspects of lipid peroxidation. Free Radic Res. 2010;44(10):1125-1171. 21. Maulik N, Das DK. Redox signaling in vascular angiogenesis. Free Radic Biol Med. 2002;33(8): 1047-1060. 22. Yun J, Rocic P, Pung YF, Belmadani S, Carrao AC, Ohanyan V, Chilian WM. Redox-dependent mechanisms in coronary collateral growth: the “redox window” hypothesis. Antioxid Redox Signal. 2009;11(8):1961-1974. 23. Koch AE, Cho M, Burrows J, Leibovich SJ, Polverini PJ. Inhibition of production of macrophage-derived angiogenic activity by the anti-rheumatic agents gold sodium thiomalate and auranofin. Biochem Biophys Res Commun. 1988;154(1):205-212. 24. Dickinson DA, Forman HJ. Cellular glutathione and thiols metabolism. Biochem Pharmacol. 2002;64(5-6):1019-1026. 25. Koch AE, Cho M, Burrows JC, Polverini PJ, Leibovich SJ. Inhibition of production of monocyte/macrophage-derived angiogenic activity by oxygen free-radical scavengers. Cell Biol Int Rep. 1992;16(5):415-425.

28. Yasuda M, Ohzeki Y, Shimizu S, Naito S, Ohtsuru A, Yamamoto T, Kuroiwa Y. Stimulation of in vitro angiogenesis by hydrogen peroxide and the relation with ETS-1 in endothelial cells. Life Sci. 1999;64(4):249-258. 29. Szatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 1991;51(3):794-798. 30. Sasaki H, Fukuda S, Otani H, et al. Hypoxic preconditioning triggers myocardial angiogenesis: a novel approach to enhance contractile functional reserve in rat with myocardial infarction. J Mol Cell Cardiol. 2002; 34(3):335-348. 31. Fukuda H, Tomimatsu T, Watanabe N, et al. Post-ischemic hypothermia blocks caspase-3 activation in the newborn rat brain after hypoxiaischemia. Brain Res. 2001;910(1-2):187-191. 32. Yamagishi S, Amano S, Inagaki Y, Okamoto T, Takeuchi M, Inoue H. Pigment epitheliumderived factor inhibits leptin-induced angiogenesis by suppressing vascular endothelial growth factor gene expression through anti-oxidative properties. Microvasc Res. 2003;65(3):186-190. 33. Al-Shabrawey M, Bartoli M, El-Remessy AB, et al. Inhibition of NAD(P)H oxidase activity blocks vascular endothelial growth factor overexpression and neovascularization during ischemic retinopathy. Am J Pathol. 2005;167(2): 599-607. 34. Cai T, Fassina G, Morini M, et al. N-acetylcysteine inhibits endothelial cell invasion and angiogenesis. Lab Invest. 1999;79(9): 1151-1159. 35. Wheeler MD, Smutney OM, Samulski RJ. Secretion of extracellular superoxide dismutase from muscle transduced with recombinant adenovirus inhibits the growth of B16 melanomas in mice. Mol Cancer Res. 2003; 1(12):871-881. 36. Kim YM, Kim KE, Koh GY, Ho YS, Lee KJ. Hydrogen peroxide produced by angiopoietin-1

From bloodjournal.hematologylibrary.org at UNIVERSITY OF NEWCASTLE on January 30, 2014. For personal use only. 630

BLOOD, 30 JANUARY 2014 x VOLUME 123, NUMBER 5

KIM and BYZOVA

mediates angiogenesis. Cancer Res. 2006; 66(12):6167-6174. 37. Garrido-Urbani S, Jemelin S, Deffert C, et al. Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARa mediated mechanism. PLoS One. 2011;6(2):e14665. 38. Ushio-Fukai M, Tang Y, Fukai T, et al. Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Circ Res. 2002; 91(12):1160-1167. 39. Tojo T, Ushio-Fukai M, Yamaoka-Tojo M, Ikeda S, Patrushev N, Alexander RW. Role of gp91phox (Nox2)-containing NAD(P)H oxidase in angiogenesis in response to hindlimb ischemia. Circulation. 2005;111(18):2347-2355. 40. Chen JX, Zeng H, Lawrence ML, Blackwell TS, Meyrick B. Angiopoietin-1-induced angiogenesis is modulated by endothelial NADPH oxidase. Am J Physiol Heart Circ Physiol. 2006;291(4): H1563-H1572. 41. Shibuya M. Vascular endothelial growth factordependent and -independent regulation of angiogenesis. BMB Rep. 2008;41(4):278-286. 42. Ruef J, Hu ZY, Yin LY, et al. Induction of vascular endothelial growth factor in ballooninjured baboon arteries. A novel role for reactive oxygen species in atherosclerosis. Circ Res. 1997;81(1):24-33. 43. Knighton DR, Hunt TK, Scheuenstuhl H, Halliday BJ, Werb Z, Banda MJ. Oxygen tension regulates the expression of angiogenesis factor by macrophages. Science. 1983;221(4617): 1283-1285. 44. Chua CC, Hamdy RC, Chua BH. Upregulation of vascular endothelial growth factor by H2O2 in rat heart endothelial cells. Free Radic Biol Med. 1998;25(8):891-897. 45. Wang Y, Zang QS, Liu Z, et al. Regulation of VEGF-induced endothelial cell migration by mitochondrial reactive oxygen species. Am J Physiol Cell Physiol. 2011;301(3):C695-C704. 46. Li J, Wang JJ, Yu Q, Chen K, Mahadev K, Zhang SX. Inhibition of reactive oxygen species by Lovastatin downregulates vascular endothelial growth factor expression and ameliorates bloodretinal barrier breakdown in db/db mice: role of NADPH oxidase 4. Diabetes. 2010;59(6): 1528-1538. 47. Lu M, Kuroki M, Amano S, et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest. 1998;101(6):1219-1224. 48. Arbiser JL, Petros J, Klafter R, et al. Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proc Natl Acad Sci USA. 2002;99(2):715-720. 49. Colavitti R, Pani G, Bedogni B, Anzevino R, Borrello S, Waltenberger J, Galeotti T. Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR. J Biol Chem. 2002;277(5):3101-3108. 50. Birukova AA, Lee S, Starosta V, et al. A role for VEGFR2 activation in endothelial responses caused by barrier disruptive OxPAPC concentrations. PLoS ONE. 2012;7(1):e30957. 51. Bochkov VN, Philippova M, Oskolkova O, et al. Oxidized phospholipids stimulate angiogenesis via autocrine mechanisms, implicating a novel role for lipid oxidation in the evolution of atherosclerotic lesions. Circ Res. 2006;99(8): 900-908. 52. Salomonsson L, Pettersson S, Englund MC, Wiklund O, Ohlsson BG. Post-transcriptional regulation of VEGF expression by oxidised LDL in human macrophages. Eur J Clin Invest. 2002; 32(10):767-774.

53. Hutter R, Speidl WS, Valdiviezo C, Sauter B, Corti R, Fuster V, Badimon JJ. Macrophages transmit potent proangiogenic effects of oxLDL in vitro and in vivo involving HIF-1a activation: a novel aspect of angiogenesis in atherosclerosis. J Cardiovasc Transl Res. 2013; 6(4):558-569. 54. Shatrov VA, Sumbayev VV, Zhou J, Brune ¨ B. Oxidized low-density lipoprotein (oxLDL) triggers hypoxia-inducible factor-1alpha (HIF-1alpha) accumulation via redox-dependent mechanisms. Blood. 2003;101(12):4847-4849. 55. Kim YW, West XZ, Byzova TV. Inflammation and oxidative stress in angiogenesis and vascular disease. J Mol Med (Berl). 2013;91(3):323-328. 56. Malinin NL, West XZ, Byzova TV. Oxidation as “the stress of life”. Aging (Albany, NY Online). 2011;3(9):906-910. 57. Marszalek JR, Lodish HF. Docosahexaenoic acid, fatty acid-interacting proteins, and neuronal function: breastmilk and fish are good for you. Annu Rev Cell Dev Biol. 2005;21:633-657. 58. Salomon RG, Hong L, Hollyfield JG. Discovery of carboxyethylpyrroles (CEPs): critical insights into AMD, autism, cancer, and wound healing from basic research on the chemistry of oxidized phospholipids. Chem Res Toxicol. 2011;24(11): 1803-1816. 59. West XZ, Malinin NL, Merkulova AA, et al. Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. Nature. 2010;467(7318):972-976. 60. Gu X, Meer SG, Miyagi M, Rayborn ME, Hollyfield JG, Crabb JW, Salomon RG. Carboxyethylpyrrole protein adducts and autoantibodies, biomarkers for age-related macular degeneration. J Biol Chem. 2003; 278(43):42027-42035. 61. Oshikawa J, Kim SJ, Furuta E, et al. Novel role of p66Shc in ROS-dependent VEGF signaling and angiogenesis in endothelial cells. Am J Physiol Heart Circ Physiol. 2012;302(3): H724-H732. 62. Bordon Y. A new vein of TLR biology. Nat Rev Immunol. 2010;10(11):748. 63. Leibovich SJ, Chen JF, Pinhal-Enfield G, et al. Synergistic up-regulation of vascular endothelial growth factor expression in murine macrophages by adenosine A(2A) receptor agonists and endotoxin. Am J Pathol. 2002;160(6):2231-2244. 64. Pollet I, Opina CJ, Zimmerman C, Leong KG, Wong F, Karsan A. Bacterial lipopolysaccharide directly induces angiogenesis through TRAF6mediated activation of NF-kappaB and c-Jun N-terminal kinase. Blood. 2003;102(5): 1740-1742. 65. Grote K, Schuett H, Salguero G, et al. Toll-like receptor 2/6 stimulation promotes angiogenesis via GM-CSF as a potential strategy for immune defense and tissue regeneration. Blood. 2010; 115(12):2543-2552. 66. Paone A, Galli R, Gabellini C, et al. Toll-like receptor 3 regulates angiogenesis and apoptosis in prostate cancer cell lines through hypoxiainducible factor 1 alpha. Neoplasia. 2010;12(7): 539-549. 67. Palm NW, Medzhitov R. Pattern recognition receptors and control of adaptive immunity. Immunol Rev. 2009;227(1):221-233. 68. Kawai T, Akira S. Pathogen recognition with Tolllike receptors. Curr Opin Immunol. 2005;17(4): 338-344. 69. Mutoh A, Ueda S. Peroxidized unsaturated fatty acids stimulate Toll-like receptor 4 signaling in endothelial cells. Life Sci. 2013;92(20-21): 984-992. 70. Spirig R, Djafarzadeh S, Regueira T, et al. Effects of TLR agonists on the hypoxia-regulated

transcription factor HIF-1alpha and dendritic cell maturation under normoxic conditions. PLoS ONE. 2010;5(6):e0010983. 71. Okuno Y, Nakamura-Ishizu A, Otsu K, Suda T, Kubota Y. Pathological neoangiogenesis depends on oxidative stress regulation by ATM. Nat Med. 2012;18(8):1208-1216. 72. Ushio-Fukai M, Urao N. Novel role of NADPH oxidase in angiogenesis and stem/progenitor cell function. Antioxid Redox Signal. 2009;11(10): 2517-2533. 73. Urao N, Inomata H, Razvi M, et al. Role of nox2-based NADPH oxidase in bone marrow and progenitor cell function involved in neovascularization induced by hindlimb ischemia. Circ Res. 2008;103(2):212-220. 74. Petry A, Djordjevic T, Weitnauer M, Kietzmann T, Hess J, Gorlach ¨ A. NOX2 and NOX4 mediate proliferative response in endothelial cells. Antioxid Redox Signal. 2006;8(9-10):1473-1484. 75. Peshavariya H, Dusting GJ, Jiang F, Halmos LR, Sobey CG, Drummond GR, Selemidis S. NADPH oxidase isoform selective regulation of endothelial cell proliferation and survival. Naunyn Schmiedebergs Arch Pharmacol. 2009; 380(2):193-204. 76. Datla SR, Peshavariya H, Dusting GJ, Mahadev K, Goldstein BJ, Jiang F. Important role of Nox4 type NADPH oxidase in angiogenic responses in human microvascular endothelial cells in vitro. Arterioscler Thromb Vasc Biol. 2007;27(11): 2319-2324. 77. Schroder ¨ K, Zhang M, Benkhoff S, et al. Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase. Circ Res. 2012; 110(9):1217-1225. 78. Craige SM, Chen K, Pei Y, et al. NADPH oxidase 4 promotes endothelial angiogenesis through endothelial nitric oxide synthase activation. Circulation. 2011;124(6):731-740. 79. Ikeda S, Yamaoka-Tojo M, Hilenski L, Patrushev NA, Anwar GM, Quinn MT, Ushio-Fukai M. IQGAP1 regulates reactive oxygen speciesdependent endothelial cell migration through interacting with Nox2. Arterioscler Thromb Vasc Biol. 2005;25(11):2295-2300. 80. Yamaoka-Tojo M, Ushio-Fukai M, Hilenski L, et al. IQGAP1, a novel vascular endothelial growth factor receptor binding protein, is involved in reactive oxygen species—dependent endothelial migration and proliferation. Circ Res. 2004;95(3):276-283. 81. Hopf HW, Gibson JJ, Angeles AP, et al. Hyperoxia and angiogenesis. Wound Repair Regen. 2005;13(6):558-564. 82. Sen CK, Khanna S, Babior BM, Hunt TK, Ellison EC, Roy S. Oxidant-induced vascular endothelial growth factor expression in human keratinocytes and cutaneous wound healing. J Biol Chem. 2002;277(36):33284-33290. 83. Nizamutdinova IT, Kim YM, Chung JI, et al. Anthocyanins from black soybean seed coats stimulate wound healing in fibroblasts and keratinocytes and prevent inflammation in endothelial cells. Food Chem Toxicol. 2009; 47(11):2806-2812. 84. Kim KS, Choi HW, Yoon HE, Kim IY. Reactive oxygen species generated by NADPH oxidase 2 and 4 are required for chondrogenic differentiation. J Biol Chem. 2010;285(51): 40294-40302. 85. Agarwal A, Gupta S, Sharma RK. Role of oxidative stress in female reproduction. Reprod Biol Endocrinol. 2005;3:28. 86. Sugino N, Shimamura K, Takiguchi S, et al. Changes in activity of superoxide dismutase in the human endometrium throughout the menstrual cycle and in early pregnancy. Hum Reprod. 1996;11(5):1073-1078.

From bloodjournal.hematologylibrary.org at UNIVERSITY OF NEWCASTLE on January 30, 2014. For personal use only. BLOOD, 30 JANUARY 2014 x VOLUME 123, NUMBER 5

87. Meduri G, Bausero P, Perrot-Applanat M. Expression of vascular endothelial growth factor receptors in the human endometrium: modulation during the menstrual cycle. Biol Reprod. 2000;62(2):439-447. 88. Moreno PR, Purushothaman M, Purushothaman KR. Plaque neovascularization: defense mechanisms, betrayal, or a war in progress. Ann N Y Acad Sci. 2012;1254:7-17. 89. Martinez-Outschoorn UE, Balliet RM, Rivadeneira DB, et al. Oxidative stress in cancer associated fibroblasts drives tumor-stroma coevolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle. 2010;9(16): 3256-3276. 90. Josson S, Matsuoka Y, Chung LW, Zhau HE, Wang R. Tumor-stroma co-evolution in prostate cancer progression and metastasis. Semin Cell Dev Biol. 2010;21(1):26-32. 91. Komatsu D, Kato M, Nakayama J, Miyagawa S, Kamata T. NADPH oxidase 1 plays a critical mediating role in oncogenic Ras-induced vascular endothelial growth factor expression. Oncogene. 2008;27(34):4724-4732. 92. Kim J, Koyanagi T, Mochly-Rosen D. PKCd activation mediates angiogenesis via NADPH oxidase activity in PC-3 prostate cancer cells. Prostate. 2011;71(9):946-954. 93. Cui Y, Xu X, Bi H, et al. Expression modification of uncoupling proteins and MnSOD in retinal endothelial cells and pericytes induced by high glucose: the role of reactive oxygen species in diabetic retinopathy. Exp Eye Res. 2006;83(4): 807-816. 94. Nielsen JC, Naash MI, Anderson RE. The regional distribution of vitamins E and C in mature and premature human retinas. Invest Ophthalmol Vis Sci. 1988;29(1):22-26. 95. Penn JS, Tolman BL, Bullard LE. Effect of a water-soluble vitamin E analog, trolox C, on retinal vascular development in an animal model

OXIDATIVE STRESS IN ANGIOGENESIS

of retinopathy of prematurity. Free Radic Biol Med. 1997;22(6):977-984. 96. Ellis EA, Guberski DL, Somogyi-Mann M, Grant MB. Increased H2O2, vascular endothelial growth factor and receptors in the retina of the BBZ/Wor diabetic rat. Free Radic Biol Med. 2000;28(1):91-101. 97. Arden GB, Sivaprasad S. Hypoxia and oxidative stress in the causation of diabetic retinopathy. Curr Diabetes Rev. 2011;7(5):291-304. 98. Ebrahem Q, Renganathan K, Sears J, et al. Carboxyethylpyrrole oxidative protein modifications stimulate neovascularization: Implications for age-related macular degeneration. Proc Natl Acad Sci USA. 2006; 103(36):13480-13484. 99. Kaur K, Salomon RG, O’Neil J, Hoff HF. (Carboxyalkyl)pyrroles in human plasma and oxidized low-density lipoproteins. Chem Res Toxicol. 1997;10(12):1387-1396. 100. Podrez EA, Febbraio M, Sheibani N, et al. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocytegenerated reactive nitrogen species. J Clin Invest. 2000;105(8):1095-1108. 101. Podrez EA, Poliakov E, Shen Z, et al. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J Biol Chem. 2002; 277(41):38517-38523. 102. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on antiVEGF therapy for cancer. Nat Clin Pract Oncol. 2006;3(1):24-40. 103. Duda DG, Batchelor TT, Willett CG, Jain RK. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med. 2007;13(6):223-230. 104. Kieran MW, Kalluri R, Cho YJ. The VEGF pathway in cancer and disease: responses,

631

resistance, and the path forward. Cold Spring Harb Perspect Med. 2012;2(12):a006593. 105. Kerr BA, Byzova TV. The dark side of the oxidative force in angiogenesis. Nat Med. 2012; 18(8):1184-1185. 106. Heath VL, Bicknell R. Anticancer strategies involving the vasculature. Nat Rev Clin Oncol. 2009;6(7):395-404. 107. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298-307. 108. Drummond GR, Selemidis S, Griendling KK, Sobey CG. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov. 2011; 10(6):453-471. 109. Selemidis S, Sobey CG, Wingler K, Schmidt HH, Drummond GR. NADPH oxidases in the vasculature: molecular features, roles in disease and pharmacological inhibition. Pharmacol Ther. 2008;120(3):254-291. 110. Fotsis T, Pepper MS, Aktas E, et al. Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res. 1997;57(14): 2916-2921. 111. Nespereira B, Perez-Ilzarbe ´ M, Fernandez ´ P, Fuentes AM, Paramo ´ JA, Rodr´ıguez JA. Vitamins C and E downregulate vascular VEGF and VEGFR-2 expression in apolipoprotein-Edeficient mice. Atherosclerosis. 2003;171(1): 67-73. 112. Oak MH, El Bedoui J, Schini-Kerth VB. Antiangiogenic properties of natural polyphenols from red wine and green tea. J Nutr Biochem. 2005;16(1):1-8. 113. Brakenhielm ˚ E, Cao R, Cao Y. Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J. 2001;15(10):1798-1800.

Oxidative stress in angiogenesis and vascular disease.

Despite the damaging effect on tissues at a high concentration, it has been gradually established that oxidative stress plays a positive role during a...
657KB Sizes 0 Downloads 0 Views